Please login to the form below

Not currently logged in

Teva wins challenge to BMS' Baraclude patent in US

US court says hepatitis B treatment’s patent is invalid

US District Court Delaware

Teva has convinced a US court that the patent protection for Bristol-Myers Squibb's hepatitis B treatment Baraclude is invalid.

BMS said it believes the court's ruling is incorrect and will appeal the decision whilst "evaluating all other legal options to vigorously defend our intellectual property rights".

The District Court of Delaware invalidated BMS' composition of matter patent for Baraclude in the US (No. 5,206,244) on the grounds of obviousness, but did not uphold Teva's claim that BMS had committed "inequitable conduct" regarding the patent application.

Baraclude (entecavir) is an important revenue generator for BMS, especially as it grapples plummeting sales of its multibillion-dollar blockbuster Plavix (clopidogrel) in the wake of last year's patent expiry in the US.

The hepatitis B treatment is one of five key products that collectively make up the engine of BMS' product portfolio at the moment, and the product contributed $1.4bn out of BMS' total sales of $17.6bn in 2012.

The court's jurisdiction only covers BMS patent protection for Baraclude in the US, which accounted for $241m of the drug's total turnover last year and is expected to reach around $260m in 2013.

BMS filed a lawsuit against Teva in 2010 when it filed for approval of its generic, introducing a 30-month block on the introduction of a copycat version of Baraclude, which it maintains is protected until February 2015.

At the moment it is unclear whether Teva will move forward with the launch of its generic ahead of any BMS appeal, weighing the risk of damages if BMS eventually prevails to the near-term sales opportunity of being the first drugmaker to launch a generic competitor.

In any event there will be some delay as the FDA has not yet approved Teva's generic marketing application, although this could occur at any time.

There have been suggestions that the case has wider significance across the pharmaceutical industry as it is the first time that a US court has invalidated a patent obtained on a drug developed via lead optimisation, in other words a modification of an older molecule (in this case the naturally-occurring nucleoside 2'-deoxyguanosine or 2-CDG).

13th February 2013

From: Sales, Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

‘Less Is More: Making Patient-Centered Digital Communication a Reality’
Letizia Affinito writes on the Gower Publishing blog....
The Seven Cs Of Cross-Functional Brand Planning
As more and more organisations have moved to cross-functional and cross-regional involvement in the development of their strategic and operational brand plans, the result has been greater engagement and alignment,...
2015/16 Pharmaceutical Titles
Browse our latest interactive Pharmaceutical and Healthcare catalogue...